We are live on ! Find out more
TRCT

Tower Research Capital (TRC) Portfolio holdings

AUM $3.85B
1-Year Est. Return 32.11%
This Fund
S&P 500
This Quarter Est. Return
+9.34%
1 Year Est. Return
+32.11%
3 Year Est. Return
+93.86%
5 Year Est. Return
+112.79%
10 Year Est. Return
+380.9%
AUM
$9.03B
AUM Growth
+$6.6B
Cap. Flow
+$1.53B
Cap. Flow %
16.94%
Top 10 Hldgs %
64.29%
Holding
5,395
New
546
Increased
3,017
Reduced
1,240
Closed
466

Sector Composition

Rank Sector Weight
1 Technology 6.25%
2 Industrials 4.6%
3 Consumer Discretionary 4.31%
4 Healthcare 4.26%
5 Financials 3.82%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
FUV
5176
DELISTED
Arcimoto, Inc. Common Stock
FUV
-5
Closed -$1K
CBD
5177
DELISTED
Companhia Brasileira de Distribuicao
CBD
-598
Closed -$7K
MOTS
5178
DELISTED
Motus GI Holdings, Inc. Common Stock
MOTS
-1
Closed
MTBL
5179
DELISTED
Moatable, Inc. American Depositary Share (each representing forty-five (45) Class A Ordinary Shares)
MTBL
-1,410
Closed -$1K
MIXT
5180
DELISTED
MIX TELEMATICS LIMITED
MIXT
-21
Closed
FSR
5181
DELISTED
Fisker Inc.
FSR
-8,004
Closed -$86K
THWWW
5182
DELISTED
Target Hospitality Corp. Warrant expiring 3/15/2024
THWWW
$0 ﹤0.01%
238
BPTH
5183
DELISTED
Bio-Path Holdings Inc
BPTH
-135
Closed -$14K
KERNW
5184
DELISTED
Akerna Corp Warrant
KERNW
$0 ﹤0.01%
8
DMK
5185
DELISTED
DMK Pharmaceuticals Corporation Common Stock
DMK
-511
Closed -$19K
WTER
5186
DELISTED
The Alkaline Water Company Inc. Common Stock
WTER
-847
Closed -$18K
ARCE
5187
DELISTED
Arco Platform Limited Class A Common Shares
ARCE
-35
Closed -$2K
JPS
5188
DELISTED
Nuveen Preferred & Income Securities Fund
JPS
-3,552
Closed -$30K
CYTO
5189
DELISTED
Altamira Therapeutics Ltd
CYTO
$0 ﹤0.01%
+1
New +$376
LTRPB
5190
DELISTED
Liberty TripAdvisor Holdings, Inc. Series B
LTRPB
-35
Closed -$2K
SVVC
5191
DELISTED
Firsthand Technology Value Fund, Inc. Common Stock
SVVC
$0 ﹤0.01%
+104
New +$486
GTH
5192
DELISTED
Genetron Holdings Limited ADS
GTH
-133
Closed -$5K
CHNA
5193
DELISTED
Loncar China BioPharma ETF
CHNA
$0 ﹤0.01%
+4
New +$126
ZYNE
5194
DELISTED
Zynerba Pharmaceuticals, Inc
ZYNE
-6,213
Closed -$21K
INFI
5195
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
-17
Closed
LFLY
5196
DELISTED
Leafly Holdings, Inc. Common Stock
LFLY
0
LOV
5197
DELISTED
Spark Networks SE American Depositary Shares
LOV
-23
Closed
IDEX
5198
DELISTED
Ideanomics, Inc. Common Stock
IDEX
-208
Closed -$52K
MSVB
5199
DELISTED
Mid-Southern Bancorp, Inc.
MSVB
-23
Closed
WTT
5200
DELISTED
Wireless Telecom Group, Inc.
WTT
$0 ﹤0.01%
154
-4,013
-96% -$5.02K

Similar funds

Tower Research Capital (TRC)'s Q3 2020 Portfolio in Review

As of Q3 2020, Tower Research Capital (TRC) held 5,395 positions worth $9.03B, up 271% from $2.44B the previous quarter. Its ten largest holdings account for 64% of the portfolio.

Tower Research Capital (TRC) deployed $1.53B of net new capital in Q3 2020, opening 546 new positions and adding to 3,017 existing holdings. Its largest new stake was iShares Biotechnology ETF: 34,723 shares worth $4.7M.

By sector, the portfolio is most concentrated in Technology at 6.3% of assets, down from 12% a quarter earlier, followed by Industrials and Consumer Discretionary.

On the sell side, the largest reduction was Vanguard S&P 500 ETF, an estimated $38.5M trimmed.

  • Tower Research Capital (TRC)'s largest Q3 2020 buy was iShares Biotechnology ETF: 34,723 shares worth $4.7M.
  • Tower Research Capital (TRC) added most to State Street SPDR S&P 500 ETF Trust in Q3 2020, an estimated $487M increase.
  • Tower Research Capital (TRC)'s biggest Q3 2020 reduction was Vanguard S&P 500 ETF, cutting an estimated $38.5M.
  • Tower Research Capital (TRC) fully exited iPath Series B S&P 500 VIX Short-Term Futures ETN in Q3 2020, selling an estimated $51.8M.
  • Tower Research Capital (TRC)'s ten largest holdings make up 64% of its $9.03B portfolio in Q3 2020.
  • Tower Research Capital (TRC) opened 546 new positions and closed 466 in Q3 2020.
  • Tower Research Capital (TRC)'s portfolio value rose 271% quarter-over-quarter to $9.03B.

Based on Tower Research Capital (TRC)'s 13F filing for Q3 2020, filed 16 Nov 2020.